SAN DIEGO, CA / ACCESS Newswire / October 14, 2026 / Ablexis, LLC, a biopharmaceutical company focused on advancing human antibody drug discovery through provision of its AlivaMab® Mouse technology, announced today an agreement granting Novo Nordisk A/S (Novo) a non-exclusive license to Ablexis' proprietary AlivaMab Mouse human antibody drug discovery platforms to discover, develop, and commercialize biologics drugs comprising AlivaMab antibodies. The license provides Novo rights to possess and use AlivaMab Mouse strains for the generation of human VH/VL antibodies.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.